Insider · CIK 0001846623
David Mehalick
Files at ZSQR (Coeptis Therapeutics Holdings, Inc.). First filing Jan 9, 2024, latest Jan 9, 2024.
In brief
David Mehalick files SEC Form 4 as CEO, president, director and 10% owner at ZSQR (Coeptis Therapeutics Holdings, Inc.). Since Jan 9, 2024, David Mehalick has reported 1 open-market buy worth $17k and 0 open-market sells worth $0, the latest filed on Jan 9, 2024.
A track record needs three past buys with six months of prices behind them; David Mehalick has 0, so none is measured yet.
The newest scored trade: bought $17k of ZSQR on Jan 5, 2024, filed Jan 9, 2024, scored 53 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZSQR: Coeptis Therapeutics Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Coeptis Therapeutics Holdings, Inc. | $17k 25,054 shares | +1% | +1% from low-68% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | MOption exercise Common stock | +148,875 | $7.05 | $1.0M | 330,192 | Feb 13, 2026 |
| Feb 11, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Common Stock | +51,250 | $0.00 | $0 | 330,192 | Feb 13, 2026 |
| Mar 4, 2025 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +28,875 | - | - | 200,125 | Mar 6, 2025 |
| Jan 5, 2024 | ZSQR Coeptis Therapeutics Holdings, Inc. | POpen-market purchase Common Stock | +5,050 | $0.69 | $3,485 | 2,762,611 | Jan 9, 2024 |
| Jan 8, 2024 | ZSQR Coeptis Therapeutics Holdings, Inc. | POpen-market purchase Common Stock | +6,000 | $0.67 | $4,020 | 2,768,611 | Jan 9, 2024 |
| Jan 8, 2024 | ZSQR Coeptis Therapeutics Holdings, Inc. | POpen-market purchase Common Stock | +14,004 | $0.66 | $9,243 | 2,782,615 | Jan 9, 2024 |
| Dec 7, 2023 | ZSQR Coeptis Therapeutics Holdings, Inc. | GGift Common Stock | -700,000 | $0.00 | $0 | 2,757,561 | Dec 11, 2023 |
Questions about David Mehalick
Answered from the filings on this page, as of the latest one.
Is David Mehalick buying or selling?
Not in the last 12 months. David Mehalick's latest open-market trade on SEC Form 4 was bought $17k of ZSQR on Jan 5, 2024.
How did David Mehalick's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Mehalick has 0.
Where does David Mehalick file Form 4?
David Mehalick has filed Form 4 at ZSQR (Coeptis Therapeutics Holdings, Inc.) as CEO and President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.